Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Real World Outcomes with Elotuzumab-Based Therapies for Patients with Relapsed Refractory Multiple Myeloma (RRMM): A Mayo Clinic Experience
Ricardo D. Parrondo, MD
Assistant Professor
Mayo Clinic Florida
Jacksonville, Florida, United States